Enterovirus D68 in hospitalized children, Barcelona, Spain, 2014–2021

Cristina Andrés,1 Jorgina Vila,1 Anna Creus-Costa, Maria Piñana, Alejandra González-Sánchez, Juliana Esperalba, Maria Gema Codina, Carla Castillo, Maria Carmen Martín, Francisco Fuentes, Susana Rubio, Karen García-Comuñas, Rodrigo Vásquez-Mercado, Narcís Saubi, Carlos Rodrigo, Tomàs Pumarola, Andrés Antón

To determine molecular epidemiology and clinical features of enterovirus D68 (EV-D68) infections, we reviewed EV-D68–associated respiratory cases at a hospital in Barcelona, Spain, during 2014–2021. Respiratory samples were collected from hospitalized patients or outpatients with symptoms of acute respiratory tract infection or suggestive of enterovirus infection. Enterovirus detection was performed by real-time multiplex reverse transcription PCR and characterization by phylogenetic analysis of the partial viral protein 1 coding region sequences. From 184 patients with EV-D68 infection, circulating subclades were B3 (80%), D1 (17%), B2 (1%), and A (<1%); clade proportions shifted over time. EV-D68 was detected mostly in children (86%) and biennially (2016, 2018, 2021). In patients <16 years of age, the most common sign/symptom was lower respiratory tract infection, for which 11.8% required pediatric intensive care unit admission and 2.3% required invasive mechanical ventilation; neurologic complications developed in 1. The potential neurotropism indicates that enterovirus surveillance should be mandatory.

In 1962, enterovirus D68 (EV-D68) was first isolated from the oropharynx of children in California, USA, who were hospitalized for lower respiratory tract infection (LRTI) (1). Although infections can occur at any age, children are the most susceptible to enterovirus infections (2). In temperate countries, enterovirus circulation usually follows a seasonal pattern, peaking in late summer and early autumn, but a second peak can also be detected during spring (3).

Until 2007, EV-D68 was rarely implicated in severe diseases and was poorly detected, associated only with small outbreaks in the United States and the Netherlands (4,5). However, in 2014, EV-D68 gained attention because of a large outbreak in the United States that was associated with severe respiratory illness and, in some cases, with neurologic complications, such as acute flaccid paralysis (AFP) (6). In Europe, circulation of EV-D68 was low and mild, but circulation increased in the following years, especially in 2021, after preventive measures for SARS-CoV-2 were eased (7). We reviewed EV-D68–associated respiratory cases, particularly in children, diagnosed at a tertiary-care university hospital in Barcelona (Catalonia, Spain) during 2014–2021. Institutional review board approval (PR(AG)173/2017) was obtained from the HUVH Clinical Research Ethics Committee.

Materials and Methods

Patients and Samples
During October 2014–November 2021, upper and lower respiratory tract specimens were collected by hospital staff and sent to the Respiratory Viruses Unit of the Vall d’Hebron University Hospital laboratory for confirmation of respiratory viruses. Samples were taken according to clinical criteria from patients with suspected acute respiratory tract infection or enterovirus infection who were hospitalized or sought care at the emergency department. In addition,

1These authors contributed equally to this article.
since September 2021, respiratory samples for SARS-CoV-2 screening were further tested for other respiratory viruses. We retrospectively collected patient demographic features (sex and age) for all laboratory-confirmed cases of enterovirus infection and collected clinical data only for patients <16 years of age (pediatric population).

Regarding the clinical definitions used, upper respiratory tract infections (URTIs) were infections from the nose to the larynx; LRTIs were recurrent wheezing, asthma, bronchiolitis, and pneumonia. To ensure that the length of hospital stay or respiratory support was associated only with EV-D68, we studied LRTI severity in patients requiring admission because of respiratory tract infection. Respiratory support was divided into 5 groups: none, oxygen through nasal cannula, high-flow nasal cannula, noninvasive mechanical ventilation, and invasive mechanical ventilation. EV-D68–associated AFP was defined as myelitis causing sudden onset of paralysis with T2 hyperintensity in medulla gray matter with dorsal brain stem variably affected on magnetic resonance images and EV-D68 detected in respiratory specimens.

Enterovirus Detection and Characterization
We performed enterovirus detection by using specific real-time multiplex reverse transcription, as previously described (8). The characterization of enterovirus was performed by the phylogenetic analyses of the partial viral protein 1 (VP1) coding-region according to the protocol recommended by the World Health Organization, with minor modifications (8).

Statistical Analyses
We performed statistical analysis by using SPSS version 22 (SPSS Inc., https://www.ibm.com). To assess associations between categorical variables, we performed χ² testing and calculated Z scores. We considered p<0.05 to be significant.

| Year | Website | Description | Details | Data Source |
|------|---------|-------------|---------|-------------|
| 2014 |         |             |         |             |
| 2015 |         |             |         |             |
| 2016 |         |             |         |             |
| 2017 |         |             |         |             |
| 2018 |         |             |         |             |
| 2019 |         |             |         |             |
| 2020 |         |             |         |             |
| 2021 |         |             |         |             |
| Total |         |             |         |             |

*Blank cells indicate zero.

Results
Over the 7 years of the study, 67,798 respiratory specimens (39,183 patients) were received for laboratory confirmation of respiratory viruses. A total of 1,423 (2%) samples from 1,313 (3%) patients were laboratory confirmed as containing enterovirus. Phylogenetic analysis of the partial VP1 coding region revealed that 187 (13%) of the 1,423 strains from 184 (14%) of the 1,313 patients were EV-D68 (147 subclade B3, 80%; 32 newly emerged subclade D1, 17%; 2 subclade B2, 1%; and 1 subclade A, <1%) (Appendix Figure 2, https://wwwnc.cdc.gov/EID/article/28/7/22-0264-App1.pdf). EV-D68 was detected mostly in pediatric populations (158/184; 86%) (median age 3 years; interquartile range 1.73–6 years; age range 8 months to 77 years), especially in patients <5 years of age (117/158; 74%). The distribution of EV-D68 infections (Appendix Figure 1) was like that of other enteroviruses; circulation peaked in autumn and spring, especially during 2016, 2018, and 2021; fewer cases were reported in 2015, 2017, 2019; and no cases were reported in 2020. Circulation of strains belonging to the several subclades shifted throughout the study period; B3 predominated until 2017, and B3 and D1 co-circulated until 2021, when B3 was predominant (Table 1; Appendix Figure 1). Moreover, the distribution of these clades among the studied population differed (p<0.00001) (Appendix Table). B3 was detected mostly among the pediatric population (<16 years of age, 95% of cases), whereas subclade D1 was detected equally in pediatric and adult (≥16 years) populations (17/32 [53%] vs. 15/32 [47%; p<0.00001).

Among the 158 children with EV-D68, 76 (48%) were hospitalized and 82 (52%) were seen as outpatients (Table 2). Until 2021, a total of 12/82 (15%) patients were outpatients, compared with 70/82 (85%) during 2021.

With regard to clinical signs and symptoms, most common were LRTI (101/158; 64%), followed by URTI (37/158; 23%). A total of 9/158 (6%) pediatric
patients had fever as the only sign, 6/158 (4%) had gastroenteritis, and 1 (1%) had myelitis and AFP (a 2-year-old girl with no underlying diseases but not fully recovered with quadriplegia and respiratory failure requiring home tracheotomy mechanical ventilation and feeding through gastrostomy). The remaining (4/158; 2.5%) patients were asymptomatic.

Discussion
Interest in EV-D68 was limited until the large outbreak that occurred in the United States in 2014 (6,9). Although EV-D68 circulation had been previously described, that large outbreak affecting mainly children was associated not only with severe respiratory disease but also with neurologic complications in some cases. Furthermore, the circulating EV-D68 strains belonged to previously circulating lineages, and therefore, there was no clear evidence of a new virus strain associated with increased severity (6,9). Nevertheless, during the same period, further studies began not only in the United States but also in Europe to monitor EV-D68 circulation (10). Results revealed a low level of EV-D68 detection and milder clinical manifestations in Europe compared with those in the United States (10). Similarly, the EV-D68 circulation in Barcelona was low during that period (8). However, in the following seasons, the trend increased, particularly during 2016 and 2018, as reported in other regions of Spain (11) and Europe (12,13), especially the upsurge observed during the 2021–22 season (7).

Four distinct clades of EV-D68 (A–D) have been described (16) in addition to subclades A, B1, B2, and B3 (10,17). Clades cocirculated variably; B3 predominated during the studied seasons, which is in concordance with other reports (10,18). Moreover, in our study, viruses belonging to the new emerging subclade D1 within clade D, were mainly

| Table 2. Demographic and clinical characteristics of patients in study of enterovirus-D68 in hospitalized children, Barcelona, Spain, 2014–2021* |
|---------------------------------------------------------------|
| Characteristic                                                                 | Hospitalized, no. (%)† | Outpatient, no. (%) |
| Sex                                                                 |                     |                    |
| M                                                                   | 44 (57.9)            | 47/82 (57.3)       |
| F                                                                   | 56 (42.1)            | 35 (42.7)          |
| Age, y                                                             |                     |                    |
| <2                                                                  | 24 (31.6)            | 24 (29.3)          |
| 2–4                                                                | 34 (44.7)            | 34 (41.4)          |
| >5                                                                  | 18 (23.7)            | 24 (29.3)          |
| Signs/symptoms‡                                                     |                     |                    |
| LRTI                                                               | 56 (73.6)            | 45 (54.9)          |
| >24 mo                                                             | 40 (71.4)            | 36 (80.0)          |
| ≤24 mo                                                             | 16 (28.6)            | 9 (20.0)           |
| URTI                                                               | 10 (13.2)            | 27 (32.9)          |
| Other                                                               | 10 (13.2)            | 10 (12.2)          |
| Treatment for LRTI                                                  |                     |                    |
| Chronic respiratory comorbidities                                  | 28/56 (50)           | 20/45 (44.4)       |
| Asthma-directed therapies                                          | 52/56 (92.9)         | 43/45 (95.6)       |
| β2 agonists                                                       | 51/56 (91.1)         | 34/45 (75.6)       |
| Systemic corticosteroids                                           | 51/56 (91.1)         | 34/45 (75.6)       |
| Hospitalization for LRTI                                           |                     |                    |
| Hospital length of stay, d§                                         | 44 (78.6)            | NA                 |
| Respiratory support§                                                |                     |                    |
| Conventional oxygen                                               | 23 (52.3)            | NA                 |
| HFNC                                                               | 13 (29.5)            | NA                 |
| NIMV                                                               | 6 (13.6)             | NA                 |
| IMV                                                               | 1 (2.3)              | NA                 |
| ECMO                                                              | 1 (2.3)              | NA                 |
| Duration of respiratory support§‡                                   | 3 (1–4)              | NA                 |
| PICU admission                                                     | 9 (11.8)             | NA                 |
| PICU length of stay, d§                                             | 4 (2–9)              | NA                 |

*Units of measure are no. (%) unless otherwise indicated. ECMO, extracorporeal membrane oxygenation; HFNC, high-flow nasal cannula; IMV, invasive mechanical ventilation; LRTI, lower respiratory tract infection; NA, not applicable; NIMV, noninvasive mechanical ventilation; PICU, pediatric intensive care unit; URTI, upper respiratory tract infection.
†Percentages are calculated vertically, according to the total cases.
‡The main symptom at time of hospital admission or consultation.
§For continuous variables, means and interquartile ranges are indicated.
¶Three patients received home mechanical ventilation and required increased respiratory support during hospitalization.
#Excludes the 3 patients with home mechanical ventilation and the patient who received ECMO.
The potential neurotropism of EV-D68 and other enteroviruses suggests that surveillance should be mandatory, which is one of the aims of the European Non-Polio Enterovirus Network (https://www.escv.eu/enpen). The year-round circulation of EV-D68 should help with close monitoring of this enterovirus, as well as prompt response to the potential occurrence of outbreaks and related clinical burden.

This study was supported by the Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III, cofinanced by the European Development Regional Fund “A way to achieve Europe,” Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003).

About the Author
Dr. Andrés is a postdoctoral researcher at the Respiratory Viruses Unit in the Microbiology Department of Hospital Universitari Vall d’Hebron. Her research interests are the epidemiology and molecular characterization based on whole-genome sequencing of viruses, especially influenza viruses, enteroviruses, rhinoviruses, and coronaviruses.

References
1. Schieble JH, Fox VL, Lennette EH. A probable new human picornavirus associated with respiratory diseases. Am J Epidemiol. 1967;85:297–310. https://doi.org/10.1093/oxfordjournals.aje.a120693
2. Khetsuriani N, Lamont-Fowlkes A, Oberst S, Pallansch MA; Centers for Disease Control and Prevention. Enterovirus surveillance—United States, 1970–2005. MMWR Surveill Summ. 2006;55:1–20.
3. European Centre for Disease Prevention and Control. Rapid risk assessment—outbreak of enterovirus A71 with severe neurological symptoms among children in Catalonia, Spain [cited 2021 Jan 15]. https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/07-06-2016-RRA-Enterovirus%20A71-Spain.pdf
4. Meijer A, van der Sanden S, Snijders BE, Jaramillo-Gutiérrez G, Bont L, van der Ent CK, et al. Emergence and epidemic occurrence of enterovirus 68 respiratory infections in The Netherlands in 2010. Virology. 2012;423:49–57. https://doi.org/10.1016/j.virology.2011.11.021
5. Rahamat-Langendoen J, Riezebos-Brilman A, Borger R, van der Heide R, Brandenburg A, Schölinck E, et al. Upsurge of human enterovirus 68 infections in patients with severe respiratory tract infections. J Clin Virol. 2011;52:103–6. https://doi.org/10.1016/j.jcv.2011.06.019
6. Midgley CM, Jackson MA, Selvarangan R, Turabelidze G, Obringer E, Johnson D, et al. Severe respiratory illness associated with enterovirus D68–Missouri and Illinois, 2014. MMWR Morb Mortal Wkly Rep. 2014;63:798–9.
7. Benschop KS, Albert J, Anton A, Andrés C, Aranzamendi M, Armsmannsdöttir B, et al. Re-emergence of enterovirus D68 in Europe after easing the COVID-19 lockdown, September 2021. Euro Surveill. 2021;26. https://doi.org/10.1080/15607917.2021.2100998
8. Andrés C, Vila J, Gimferrer L, Piñana M, Esperalba J, Codina MG, et al. Surveillance of enteroviruses from paediatric patients attended at a tertiary hospital in Catalonia from 2014 to 2017. J Clin Virol. 2019;110:29–35. https://doi.org/10.1016/j.jcv.2018.11.004
9. Midgley CM, Watson JT, Nix WA, Curns AT, Rogers SL, Brown BA, et al.; EV-D68 Working Group. Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014): a descriptive epidemiological investigation. Lancet Respir Med. 2015;3:879–87. https://doi.org/10.1016/S2213-2600(15)00335-5
10. Poelman R, Schuffenecker I, Van Leer-Buter C, Josset L, Nieters HG, Lina B; ESCV-ECDC EV-D68 Study Group. European surveillance for enterovirus D68 during the emerging North-American outbreak in 2014. J Clin Virol. 2015;71:1–9. https://doi.org/10.1016/j.jcv.2015.07.296
11. Cabreroz M, García-Iñiguez JP, Munell F, Amado A, Madurga-Revilla P, Rodrigo C, et al. First cases of severe flaccid paralysis associated with enterovirus D68 infection in Spain, 2015–2016. Pediatr Infect Dis J. 2017;36:1214–6. https://doi.org/10.1097/INF.0000000000001668
12. Pellegrinelli L, Giardina F, Lunghi G, Uceda Renteria SC, Greco L, Fratini A, et al. Emergence of divergent enterovirus (EV) D68 sub-clade D1 strains, northern Italy, September to October 2018. Euro Surveill. 2019;24. https://doi.org/10.2807/1560-7917.ES.2018.24.7.1900090

13. Cottrell S, Moore C, Perry M, Hilvers E, Williams C, Shankar AG. Prospective enterovirus D68 (EV-D68) surveillance from September 2015 to November 2018 indicates a current wave of activity in Wales. Euro Surveill. 2018;23. https://doi.org/10.2807/1560-7917.ES.2018.23.46.1800578

14. Kramer R, Sabatier M, Wirth T, Pichon M, Lina B, Schuffenecker I, et al. Molecular diversity and biennial circulation of enterovirus D68: a systematic screening study in Lyon, France, 2010 to 2016. Euro Surveill. 2018;23. https://doi.org/10.2807/1560-7917.ES.2018.23.37.1700711

15. Messacar K, Pretty K, Reno S, Dominguez SR. Continued biennial circulation of enterovirus D68 in Colorado. J Clin Virol. 2019;113:24–6. https://doi.org/10.1016/j.jcv.2019.01.008

16. Tokarz R, Firth C, Madhi SA, Howie SRC, Wu W, Sall AA, et al. Worldwide emergence of multiple clades of enterovirus 68. J Gen Virol. 2012;93:1952–8. https://doi.org/10.1099/vir.0.043935-0

17. Gong YN, Yang SL, Shih SR, Huang YC, Chang PY, Huang CG, et al. Molecular evolution and the global reemergence of enterovirus D68 by genome-wide analysis. Medicine (Baltimore). 2016;95:e4416. https://doi.org/10.1097/MD.0000000000004416

18. Knoester M, Helfferich J, Poelman R, Van Leer-Buter C, Brouwer OF, Niesters HGM; 2016 EV-D68 AFM Working Group. Twenty-nine cases of enterovirus-D68-associated acute flaccid myelitis in Europe 2016: a case series and epidemiologic overview. Pediatr Infect Dis J. 2019;38:16–21. https://doi.org/10.1097/INF.0000000000002188

19. Bal A, Sabatier M, Wirth T, Coste-Burel M, Lazrek M, Stefic K, et al. Emergence of enterovirus D68 clade D1, France, August to November 2018. Euro Surveill. 2019;24. https://doi.org/10.2807/1560-7917.ES.2019.24.3.1800699

20. Schuffenecker I, Mirand A, Josset L, Henquell C, Hecquet D, Pilorgé L, et al. Epidemiological and clinical characteristics of patients infected with enterovirus D68, France, July to December 2014. Euro Surveill. 2016;21. https://doi.org/10.2807/1560-7917.ES.2016.21.19.30226

21. Duval M, Mirand A, Lesens O, Bay JO, Caillaud D, Gallot D, et al. Retrospective study of the upsurge of enterovirus D68 clade D1 among adults (2014–2018). Viruses. 2021;13:1607. https://doi.org/10.3390/v13081607

22. Greninger AL, Naccache SN, Messacar K, Clayton A, Yu G, Somasekar S, et al. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012–14): a retrospective cohort study. Lancet Infect Dis. 2015;15:671–82. https://doi.org/10.1016/S1473-3099(15)00993-9

Address for correspondence: Tomàs Pumarola, Respiratory Viruses Unit, Virology Section, Microbiology Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain; email: virusrespiratoris@vhebron.net
Appendix

**Appendix Table.** Age distribution of the different EV-D68 subclades B3 and D1 among all cases and hospitalized children

| Age groups | Tested cases | EV laboratory-confirmed cases | %* EV-D68 | %† Subclades (all) | %‡ Paediatric EV-D68 | No. | %‡ Subclades (hospitalized) |
|------------|--------------|------------------------------|-----------|-------------------|---------------------|-----|-----------------------------|
| <2 y       | 8259         | 419                          | 5.1%      | 50                | 11.9%               | 49  | 98.0%                      |
| 2–4 y      | 4887         | 640                          | 13.1%     | 68                | 10.6%               | 63  | 97.1%                      |
| 5–14 y     | 5248         | 175                          | 3.3%      | 41                | 23.4%               | 35  | 100.0%                     |
| 15–64 y    | 10709        | 66                           | 0.6%      | 19                | 28.8%               | 7   | 10.5%                      |
| >64 y      | 10080        | 13                           | 0.1%      | 6                 | 46.2%               | 1   | -                          |
| TOTAL      | 39183        | 1313                         | 3%        | 184               | 14%                 | 147 | 80%                        |

*Percentages are calculated horizontally according to the tested samples.
†to EV laboratory-confirmed cases.
‡to EV-D68.
§Paediatric EV-D68.

Appendix Figure 1. Monthly distribution (per year) of EV-D68 (sub)clades throughout the study period. Cases from hospitalized children are labeled as a square pattern with the same (sub)clade color. Only numbers >1 are represented.
Appendix Figure 2. Phylogenetic tree of partial EV-D68 VP1 coding-region sequences. The sequences from the present study are square labeled in green (2014), in yellow (2015), in light blue (2016), in pink (2017), in turquoise (2018), in orange (2019) and in blue (2021). The reference sequences from the different clades and subclades are dot labeled in red, together with the newly emerged D1 sequences.